| Record ID | marc_university_of_toronto/uoft.marc:4242040184:2086 |
| Source | University of Toronto |
| Download Link | /show-records/marc_university_of_toronto/uoft.marc:4242040184:2086?format=raw |
LEADER: 02086cam 2200457 a 4500
005 20020523090449.6
008 020523s2001 onc bs 000 0 eng
020 $a1894620070 (print)
020 $a1894620089 (online)
020 $a1894620054 (print)
020 $a1894620062 (online)
042 $anlmcopyc
050 4 $aRJ506.H9$bE45 2001
060 00 $a2001 M-400
060 10 $aWS 350.8.A8$bE35n 2001
090 08 $aRJ 506 .H9E45 2001$bGERSTM$c1
100 1 $aEinarson, Thomas R.
245 10 $aNovel antipsychotics for patients with attention-deficit hyperactivity disorder :$ba systematic review /$cThomas R. Einarson, Michael Iskedjian.
260 $aOttawa :$bCanadian Coordinating Office for Health Technology Assessment,$c[2001]
300 $aviii, 36 p. ;$c28 cm.
490 1 $aTechnology report ;$vissue 17
500 $a"July 2001".
504 $aIncludes bibliographical references (p. 19-26).
530 $aAlso available on the Internet.
650 22 $aAntipsychotic Agents$xtherapeutic use$zCanada.
650 12 $aAttention Deficit Disorder with Hyperactivity$xdrug therapy$zCanada.
650 0 $aAttention-deficit hyperactivity disorder$xChemotherapy$xEvaluation.
650 22 $aEvaluation Studies$zCanada.
650 0 $aOlanzapine$xTherapeutic use$xEffectiveness.
650 22 $aPirenzepine$xanalogs & derivatives$zCanada.
650 0 $aRisperidone$xTherapeutic use$xEffectiveness.
650 22 $aRisperidone$xtherapeutic use$zCanada.
655 7 $aStatistics.$2mesh
700 1 $aIskedjian, Michael.
710 2 $aCanadian Coordinating Office for Health Technology Assessment.
830 0 $aTechnology report (Canadian Coordinating Office for Health Technology Assessment) ;$vissue 17.
856 4 $uhttp://www.ccohta.ca/newweb/pubapp/pdf/antipychotic%5Fadhd%5Ftr%5Fe.pdf
948 $a05/23/2002$b07/07/2002
039 $fsom/som(som)
949 $aRJ506 .H9 E45 2001$wLC$c1$i31761054448782$d4/11/2002$e22/10/2002$lSTACKS$mGERSTEIN$n2$rY$sY$tBOOK$u30/5/2002
949 $aWM190 .E35 2001$wLC$c1$i92010633$lSTACKS$mSUNNYBROOK$rY$sY$tBOOK$u10/10/2007